Cutaneous Vasculitis Update: Diagnostic Criteria, Classification

Total Page:16

File Type:pdf, Size:1020Kb

Cutaneous Vasculitis Update: Diagnostic Criteria, Classification CRITICAL REVIEW Cutaneous Vasculitis Update: Diagnostic Criteria, Classification, Epidemiology, Etiology, Pathogenesis, Evaluation and Prognosis J. Andrew Carlson, MD, FRPC,* Bernard T. Ng, MD,‡ and Ko-Ron Chen, MD, PhD† CLA: cutaneous leukocytoclastic angiitis (a.k.a. cutaneous leuko- Abstract: Vasculitis, inflammation of the vessel wall, can result in cytoclastic vasculitis) mural destruction with hemorrhage, aneurysm formation, and CSS: Churg-Strauss syndrome infarction, or intimal-medial hyperplasia and subsequent stenosis CTD: connective tissue disease (collagen vascular disease) leading to tissue ischemia. The skin, in part due to its large vascular CTDV: CTD associated vasculitis bed, exposure to cold temperatures, and frequent presence of stasis, is CV: cryoglobulinemic vasculitis DIF: direct immunofluorescent studies involved in many distinct as well as un-named vasculitic syndromes GCA: giant cell (temporal) arteritis that vary from localized and self-limited to generalized and life- HE: hematoxylan and eosin stained tissue sections threatening with multi-organ disease. To exclude mimics of vas- HSP: Henoch-Scho¨nlein purpura culitis, diagnosis of cutaneous vasculitis requires biopsy confirmation IC: immune complexes where its acute signs (fibrinoid necrosis), chronic signs (endarteritis LCV: leukocytoclastic vasculitis (a.k.a. hypersensitivity angiitis/ obliterans), or past signs (acellular scar of healed arteritis) must be cutaneous leukocytoclastic vasculitis) recognized and presence of extravascular findings such as patterned MPA: microscopic polyangiitis fibrosis or collagenolytic granulomas noted. Although vasculitis can MPO: myeloperoxidase be classified by etiology, many cases have no identifiable cause, and PAN: polyarteritis nodosa a single etiologic agent can elicit several distinct clinicopathologic PR3: proteinase 3 PSV: primary systemic vasculitis expressions of vasculitis. Therefore, the classification of cutaneous RA: rheumatoid arthritis vasculitis is best approached morphologically by determining vessel SLE: systemic lupus erythematosus size and principal inflammatory response. These histologic patterns UV: urticarial vasculitis roughly correlate with pathogenic mechanisms that, when coupled WG: Wegener granulomatosis with direct immunofluorescent examination, anti-neutrophil cyto- plasmic antibody (ANCA) status, and findings from work-up for (Am J Dermatopathol 2005;27:504–528) systemic disease, allow for specific diagnosis, and ultimately, more effective therapy. Herein, we review cutaneous vasculitis focusing on diagnostic criteria, classification, epidemiology, etiology, pathogen- ew diseases in clinical medicine cause as much diagnostic esis, and evaluation of the cutaneous vasculitis patient. Fand therapeutic consternation as vasculitis.1–6 Vasculitis is Key Words: classification, etiology, epidemiology, pathogenesis, simply inflammation directed at blood vessels identified by direct immunofluorescence, ANCA, systemic vasculitis, localized histologic examination. When blood vessel inflammation occurs, vasculitis, endarteritis obliterans vessel wall destruction with hemorrhage and aneurysm for- mation or stenosis due to intimal hyperplasia can occur, both of which may lead to tissue ischemia and infarction. Vasculitis Abbreviations can be a primary process (no known cause or association), or a phenomenon secondary to drug ingestion, infection, or the ACR: American College of Rheumatology presence of a systemic disease (eg, rheumatoid arthritis) or to AECA: antiendothelial antibodies local factor such as trauma. Systemic and localized vasculitis ANCA: antineutrophil cytoplasmic antibodies often affects the skin and subcutis, likely due in part to their APS: antiphospholipid antibody syndrome large vascular bed, hemodynamic factors (eg, stasis in lower CHCC: Chapel Hill Consensus Conference extremities), and environmental influences (eg, cold exposure). Frequent skin involvement by vasculitic syndromes, seen as From the *Divisions of Dermatology and Dermatopathology, Albany Medical diverse and dynamic patterns of discoloration, swelling, hem- College, Albany, New York; †Department of Dermatology, Saiseikai orrhage, and/or necrosis, may be their initial and/or most Central Hospital, Tokyo, Japan; and ‡Department of Pathology, Albany accessible manifestations. Thus, dermatopathologists and Medical College, Albany, New York. dermatologists often become involved in the diagnosis and Reprints: J. Andrew Carlson, Divisions of Dermatology and Dermatopathology, 2,5,7 Albany Medical College MC-81, Albany, NY 12208 (e-mail: carlsoa@mail. management of vasculitis. amc.edu). Cutaneous vasculitis presents as a mosaic of clinical Copyright Ó 2005 by Lippincott Williams & Wilkins and histologic findings due to varied pathogenic mechanisms. 504 Am J Dermatopathol Volume 27, Number 6, December 2005 Am J Dermatopathol Volume 27, Number 6, December 2005 Cutaneous Vasculitis Update Physical signs of vasculitis include urticaria, purpura, purpuric associated diseases or triggering factors, and monitoring by papules, infiltrated erythema, ulcer, infarct, livedo reticularis, histology and/or laboratory tests, may be decisive for optimal and nodules that affect the skin with varying intensity, depth, therapy of vasculitis. and distribution creating a number of named syndromes, for In this first part of this 2-part review, diagnostic criteria, example, erythema induratum (nodular vasculitis), Henoch- classification, etiology, epidemiology, pathogenesis, and eval- Schonlein purpura (HSP), or Wegener granulomatosis (WG). uation of patients presenting with cutaneous vasculitis will be However, in many cases, specific clinical entities do not always discussed. In the second part, specific vasculitic entities, pri- correlate exactly with mechanisms and any one patient may mary and secondary, that can affect the skin will be presented have a constellation of morphologic signs that overlaps in the context of morphologic and pathophysiologic classifi- with another clinical entity thus preventing confident clinical cation scheme. A primarily morphologic-based scheme is used diagnosis.8,9 A definitive diagnosis of vasculitis requires his- rather than the etiologic-based one, as it is the most practical tologic confirmation in almost all cases because few vasculitic method to generate a relevant differential diagnosis when in- syndromes have pathognomonic clinical, radiographic, and/or terpreting a skin biopsy showing vasculitis (Fig. 1). laboratory findings.6,10 However, a biopsy diagnosis of vas- culitis cannot stand by itself, as it must be correlated with clinical history, physical and laboratory findings, and/or an- DIAGNOSIS AND CLASSIFICATION giographic features. For instance, a diagnosis of vasculitis OF VASCULITIS restricted to the skin (aka, hypersensitivity vasculitis, cuta- The diagnosis of vasculitis is a medical challenge due to neous leukocytoclastic angiitis) requires that the systemic the unknown or incompletely understood etiology and patho- manifestations of vasculitis be sought and found absent.5 If genesis of most vasculitides as well as their protean and systemic vasculitis is present, imaging studies can provide a overlapping clinicopathologic features.14,15 For instance, hepa- useful means to determine disease extension and activity10 and titis C infection can be found in association with several dif- serology, such as C-reactive protein and anti-neutrophilic ferent types of vasculitis such as polyarteritis nodosa (PAN), cytoplasmic antibodies (ANCA) levels and type can be used to cryoglobulinemic vasculitis (CV), and hypersensitivity/cuta- monitor disease activity and predict mortality risk, respec- neous leukocytoclastic angiitis (CLA).16 (Henceforth, leuko- tively.11,12 In addition, clinical features such as the presence of cytoclastic vasculitis (LCV) will be used to describe patients arthralgias and cryoglobulinemia, and absence of fever can with the histologic reaction pattern of small vessel neutrophilic predict a chronic course.13 Lastly, the histopathologic in- vasculitis with or without systemic disease; the Chapel Hill terpretation for vasculitis is dependent on the type of biopsy, Consensus Conference (CHCC) term ‘‘cutaneous leukocyto- age of the cutaneous lesion sampled, effects of prior treatment clastic angiitis (CLA)’’ will be used to describe patients with and experience of the pathologist. Not only the diagnosis of cutaneous LCV without systemic disease.) To efficaciously vasculitis, but also the recognition of the specific type, manage vasculitis, a precise and accurate diagnostic FIGURE 1. The size of vessel in- volvement is one histologic feature in conjunction with the dominant inflammatory cell that allow for classification of most common forms of cutaneous vasculitis. In general, Henoch-Scho¨nlein purpura (HSP) and cutaneous leukocytoclastic an- giitis (CLA) (aka, leukocytoclastic or hypersensitivity vasculitis) affect the superficial vessels of the skin whereas polyarteritis nodosa (PAN), nodular vasculitis (Nod Vas), and giant cell arteritis (GCA) affect deep muscular vessels found at the dermal-subcutis interface and within the subcutis. Most other forms of vasculitis such as cryoglobulinemic vasculitis (CV), connective tissue disease (CTDV) vasculitis, and anti-neutrophilic anti- body associated vasculitides (ANCA+ vasculitis: Wegener vasculitis, Churg-Strauss syndrome, and microscopic polyangiitis) can affect both small and muscular vessels (although not necessarily in the same biopsy). The diagnostic yield
Recommended publications
  • Cutaneous Manifestations of COVID-19: a Systematic Review and Analysis of Individual Patient-Level Data
    Volume 26 Number 12| December 2020 Dermatology Online Journal || Review 26(12):2 Cutaneous manifestations of COVID-19: a systematic review and analysis of individual patient-level data David S Lee1 MD, Paradi Mirmirani2,3 MD, Patrick E McCleskey4 MD, Majid Mehrpouya5 PhD, Farzam Gorouhi6,7 MD Affiliations: 1Department of Dermatology, The Permanente Medical Group, Pleasanton, California, USA, 2Department of Dermatology, University of California, San Francisco, California, USA, 3Department of Dermatology, The Permanente Medical Group, Vallejo, California, USA, 4Department of Dermatology, The Permanente Medical Group, Oakland, California, USA, 5Faculty of Engineering, University of Calgary, Calgary, Alberta, Canada, 6Department of Dermatology, The Permanente Medical Group, South Sacramento, California, USA, 7Department of Dermatology, University of California, Davis, California, USA Corresponding Author: Farzam Gorouhi MD FAAD, Kaiser Permanente, South Sacramento, 6600 Bruceville Road, Sacramento, CA 95823, Tel: 415-298-1345, Email: [email protected] Introduction Abstract In December 2019, reports from Wuhan, China Distinctive patterns in the cutaneous manifestations described new clusters of patients with severe of COVID-19 have been recently reported. We pneumonia linked to a novel coronavirus strain, now conducted a systematic review to identify case reports and case series characterizing cutaneous referred to as severe acute respiratory syndrome manifestations of confirmed COVID-19. Key coronavirus 2 (SARS-CoV-2), [1]. Coronavirus disease demographic and clinical data from each case were 2019 (COVID-19) has since reached pandemic extracted and analyzed. The primary outcome proportions, with over 12·7 million cases worldwide, measure was risk factor analysis of skin related 566,000 deaths, and 188 countries affected at the outcomes for severe COVID-19 disease.
    [Show full text]
  • Classification of Vasculitis Joseph L
    Classification of Vasculitis Joseph L. Jorizzo A working classification of necrotizing vasculitis based on size of the affected vessel is proposed. The classification proposed by Gilliam and Fink in 1976 is a basis for the curren proposal. A revised working classification of vasculitis is presented. Small vessel necrotizing vasculitis and larger vessel necrotizing vasculitis categories are further subdivided. Improved understanding of the basic science aspects of vasculitis will hopefully give rise to a better consensus on the classification of vasculitis. J Invest Dermatol 100:106S–110S, 1993 A considerable portion of the now classic Medical Grand Rounds on SMALL VESSEL NECROTIZING VASCULITIS necrotizing vasculitis presented at The University of Texas Southwestern (NECROTIZING VENULITIS) Medical Center by James W. Gilliam in 1976 dealt with the classification of necrotizing vasculitis. Aspects of this presentation have been The hallmark of small-vessel necrotizing vasculitis is the diagnostic published (Table I) [1]. histopathologic finding of leukocytoclastic vasculitis including endothe- The historical context of Gilliam’s classification is important given the lial cell swelling, neutrophilic invasion of blood-vessel walls, leukocy- confounding array of classification schemas that preceded (and followed!) toclasia (neutrophilic nuclear karyorrhexis), extravasation of erythrocytes, and fibrinoid necrosis of blood vessel walls [14]. This it. The classification of vasculitis remains frustratingly controversial today. Zeek was the first to incorporate a clinicopathologic assessment process has been shown to affect post capillary venules [15,16]. This based on the size of the vessel involved in the inflammatory process in entity has been proposed as a cutaneous model for circulating immune his classification of necrotizing vasculitis in 1952 [2].
    [Show full text]
  • Early-Phase GVHD Gene Expression Profile in Target Versus Non
    Bone Marrow Transplantation (2013) 48, 284–293 & 2013 Macmillan Publishers Limited All rights reserved 0268-3369/13 www.nature.com/bmt ORIGINAL ARTICLE Early-phase GVHD gene expression profile in target versus non-target tissues: kidney, a possible target? B Sadeghi1, H Al-Chaqmaqchi1, S Al-Hashmi1, D Brodin2, Z Hassan1,3, M Abedi-Valugerdi4, A Moshfegh5 and M Hassan1,3 GVHD is a major complication after allo-SCT. In GVHD, some tissues like liver, intestine and skin are infiltrated by donor T cells while others like muscle are not. The mechanism underlying targeted tropism of donor T cells is not fully understood. In the present study, we aim to explore differences in gene expression profile among target versus non-target tissues in a mouse model of GVHD based on chemotherapy conditioning. Expression levels of JAK–signal transducers and activators of transcription (STAT), CXCL1, ICAM1 and STAT3 were increased in the liver and remained unchanged (or decreased) in the muscle and kidney after conditioning. At the start of GVHD the expression levels of CXCL9, ITGb2, SAA3, MARCO, TLR and VCAM1 were significantly higher in the liver or kidney compared with the muscle of GVHD animals. Moreover, biological processes of inflammatory reactions, leukocyte migration, response to bacterium and chemotaxis followed the same pattern. Our data show that both chemotherapy and allogenicity exclusively induce expression of inflammatory genes in target tissues. Moreover, gene expression profile and histopathological findings in the kidney are similar to those observed in the liver of GVHD mice. Bone Marrow Transplantation (2013) 48, 284–293; doi:10.1038/bmt.2012.120; published online 23 July 2012 Keywords: gene expression; GVHD; kidney; target tissues; mouse model INTRODUCTION none of these reports describe any changes in gene expression Allo-SCT is the treatment of choice for a variety of malignant and profile of non-target tissues like muscle.
    [Show full text]
  • WO 2017/048702 Al
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date W O 2017/048702 A l 2 3 March 2017 (23.03.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 487/04 (2006.01) A61P 35/00 (2006.01) kind of national protection available): AE, AG, AL, AM, A61K 31/519 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, (21) International Application Number: DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/US20 16/05 1490 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, (22) International Filing Date: KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, 13 September 2016 (13.09.201 6) MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, (25) Filing Language: English SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, (26) Publication Language: English TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/218,493 14 September 2015 (14.09.2015) US (84) Designated States (unless otherwise indicated, for every 62/218,486 14 September 2015 (14.09.2015) US kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, (71) Applicant: INFINITY PHARMACEUTICALS, INC.
    [Show full text]
  • Dermatologic Manifestations and Complications of COVID-19
    American Journal of Emergency Medicine 38 (2020) 1715–1721 Contents lists available at ScienceDirect American Journal of Emergency Medicine journal homepage: www.elsevier.com/locate/ajem Dermatologic manifestations and complications of COVID-19 Michael Gottlieb, MD a,⁎,BritLong,MDb a Department of Emergency Medicine, Rush University Medical Center, United States of America b Department of Emergency Medicine, Brooke Army Medical Center, United States of America article info abstract Article history: The novel coronavirus disease of 2019 (COVID-19) is associated with significant morbidity and mortality. While Received 9 May 2020 much of the focus has been on the cardiac and pulmonary complications, there are several important dermato- Accepted 3 June 2020 logic components that clinicians must be aware of. Available online xxxx Objective: This brief report summarizes the dermatologic manifestations and complications associated with COVID-19 with an emphasis on Emergency Medicine clinicians. Keywords: COVID-19 Discussion: Dermatologic manifestations of COVID-19 are increasingly recognized within the literature. The pri- fi SARS-CoV-2 mary etiologies include vasculitis versus direct viral involvement. There are several types of skin ndings de- Coronavirus scribed in association with COVID-19. These include maculopapular rashes, urticaria, vesicles, petechiae, Dermatology purpura, chilblains, livedo racemosa, and distal limb ischemia. While most of these dermatologic findings are Skin self-resolving, they can help increase one's suspicion for COVID-19. Emergency medicine Conclusion: It is important to be aware of the dermatologic manifestations and complications of COVID-19. Knowledge of the components is important to help identify potential COVID-19 patients and properly treat complications. © 2020 Elsevier Inc.
    [Show full text]
  • Allergic Reactions After Vaccination: Translating Guidelines Into Clinical Practice
    R E V I E W EUR ANN ALLERGY CLIN IMMUNOL VOL 51, N 2, 51-61, 2019 A. RADICE1, G. CARLI2, D. MACCHIA1, A. FARSI2 Allergic reactions after vaccination: translating guidelines into clinical practice 1SOS Allergologia e Immunologia, Firenze, Azienda USL Toscana Centro, Italy 2SOS Allergologia e Immunologia, Prato, Azienda USL Toscana Centro, Italy KEYWORDS Summary vaccine; vaccination; allergic reactions; Vaccination represents one of the most powerful medical interventions on global health. anaphylaxis; vaccine hesitancy; vaccine Despite being safe, sustainable, and effective against infectious and in some cases also components; desensitization non-infectious diseases, it’s nowadays facing general opinion’s hesitancy because of a false perceived risk of adverse events. Adverse reactions to vaccines are relatively rare, instead, and those recognizing a hypersensitivity mechanism are even rarer. Corresponding author The purpose of this review is to offer a practical approach to adverse events after vaccina- Anna Radice Ospedale San Giovanni di Dio tion, focusing on immune-mediated reactions with particular regard to their recognition, Via Torregalli 3, 50143 Firenze diagnosis and management. Phone: +39 055 6932304 According to clinical features, we propose an algorythm for allergologic work-up, which E-mail: [email protected] helps in confirming hypersensitivity to vaccine, nonetheless ensuring access to vaccination. Finally, a screening questionnaire is included, providing criteria for immunisation in spe- Doi cialized care settings. 10.23822/EurAnnACI.1764-1489.86 Introduction The gain from vaccination is not just about human health, but it is also a matter of financial resources for health systems. “Smallpox is dead” stated the magazine of the World Health It has been calculated that for every dollar spent in vaccines, Organisation (WHO) in 1980.
    [Show full text]
  • Visual Recognition of Autoimmune Connective Tissue Diseases
    Seeing the Signs: Visual Recognition of Autoimmune Connective Tissue Diseases Utah Association of Family Practitioners CME Meeting at Snowbird, UT 1:00-1:30 pm, Saturday, February 13, 2016 Snowbird/Alta Rick Sontheimer, M.D. Professor of Dermatology Univ. of Utah School of Medicine Potential Conflicts of Interest 2016 • Consultant • Paid speaker – Centocor (Remicade- – Winthrop (Sanofi) infliximab) • Plaquenil – Genentech (Raptiva- (hydroxychloroquine) efalizumab) – Amgen (etanercept-Enbrel) – Alexion (eculizumab) – Connetics/Stiefel – MediQuest • Royalties Therapeutics – Lippincott, – P&G (ChelaDerm) Williams – Celgene* & Wilkins* – Sanofi/Biogen* – Clearview Health* Partners • 3Gen – Research partner *Active within past 5 years Learning Objectives • Compare and contrast the presenting and Hallmark cutaneous manifestations of lupus erythematosus and dermatomyositis • Compare and contrast the presenting and Hallmark cutaneous manifestations of morphea and systemic sclerosis Distinguishing the Cutaneous Manifestations of LE and DM Skin involvement is 2nd most prevalent clinical manifestation of SLE and 2nd most common presenting clinical manifestation Comprehensive List of Skin Lesions Associated with LE LE-SPECIFIC LE-NONSPECIFIC Cutaneous vascular disease Acute Cutaneous LE Vasculitis Leukocytoclastic Localized ACLE Palpable purpura Urticarial vasculitis Generalized ACLE Periarteritis nodosa-like Ten-like ACLE Vasculopathy Dego's disease-like Subacute Cutaneous LE Atrophy blanche-like Periungual telangiectasia Annular Livedo reticularis
    [Show full text]
  • Pulmonary Microscopic Polyangiitis Presenting As Acute Respiratory Failure from Diffuse Alveolar Hemorrhage
    Case report SARCOIDOSIS VASCULITIS AND DIFFUSE LUNG DISEASES 2015; 32; 372-377 © Mattioli 1885 Pulmonary microscopic polyangiitis presenting as acute respiratory failure from diffuse alveolar hemorrhage Katharine K. Roberts1, Michael M. Chamberlin2, Allen R. Holmes3, Jonathan L. Henderson4, Robert L. Hutton3, William N. Hannah1, Michael J. Morris4 1 Internal Medicine Residency, Department of Medicine, San Antonio Military Medical Center; 2 Internal Medicine, United States Army Health Clinic, Vilseck, Germany; 3 Pathology Residency, Department of Pathology, San Antonio Military Medical Center; 4 Pulmonary/ Critical Care Service, Department of Medicine, San Antonio Military Medical Center Abstract. MicrMicroscopicoscopic polyangiitis and granulomatosis with polyangiitis are rare anti-neutrophilic cytoplas-cytoplas- mic antibody-associated systemic vasculitides that predominantly affect small to medium sized vessels of the lungs and kidneys. These syndromes are largely confined to older adults and often present sub-acutely follow- ing weeks to months of nonspecific prodromal symptoms. While both diseases often manifest within multiple organ systems concurrently, the disease spectrum of microscopic polyangiitis almost always includes the kidneys, while granulomatosis with polyangiitis is most commonly associated with pulmonary disease. We present two cases of rapid onset respiratory failure secondary to diffuse alveolar hemorrhage in young active duty military personnel. After serological testing and surgical lung biopsy, both patients were
    [Show full text]
  • ANCA--Associated Small-Vessel Vasculitis
    ANCA–Associated Small-Vessel Vasculitis ISHAK A. MANSI, M.D., PH.D., ADRIANA OPRAN, M.D., and FRED ROSNER, M.D. Mount Sinai Services at Queens Hospital Center, Jamaica, New York and the Mount Sinai School of Medicine, New York, New York Antineutrophil cytoplasmic antibodies (ANCA)–associated vasculitis is the most common primary sys- temic small-vessel vasculitis to occur in adults. Although the etiology is not always known, the inci- dence of vasculitis is increasing, and the diagnosis and management of patients may be challenging because of its relative infrequency, changing nomenclature, and variability of clinical expression. Advances in clinical management have been achieved during the past few years, and many ongoing studies are pending. Vasculitis may affect the large, medium, or small blood vessels. Small-vessel vas- culitis may be further classified as ANCA-associated or non-ANCA–associated vasculitis. ANCA–asso- ciated small-vessel vasculitis includes microscopic polyangiitis, Wegener’s granulomatosis, Churg- Strauss syndrome, and drug-induced vasculitis. Better definition criteria and advancement in the technologies make these diagnoses increasingly common. Features that may aid in defining the spe- cific type of vasculitic disorder include the type of organ involvement, presence and type of ANCA (myeloperoxidase–ANCA or proteinase 3–ANCA), presence of serum cryoglobulins, and the presence of evidence for granulomatous inflammation. Family physicians should be familiar with this group of vasculitic disorders to reach a prompt diagnosis and initiate treatment to prevent end-organ dam- age. Treatment usually includes corticosteroid and immunosuppressive therapy. (Am Fam Physician 2002;65:1615-20. Copyright© 2002 American Academy of Family Physicians.) asculitis is a process caused These antibodies can be detected with indi- by inflammation of blood rect immunofluorescence microscopy.
    [Show full text]
  • Cutaneous Reactions Reported After Moderna and Pfizer COVID-19 Vaccination: a Registry-Based Study of 414 Cases
    Journal Pre-proof Cutaneous Reactions Reported after Moderna and Pfizer COVID-19 Vaccination: A Registry-Based Study of 414 Cases Devon E. McMahon, BA, Erin Amerson, MD, Misha Rosenbach, MD, Jules B. Lipoff, MD, Danna Moustafa, BS, Anisha Tyagi, BA, Seemal R. Desai, MD, Lars E. French, MD, Henry W. Lim, MD, Bruce H. Thiers, MD, George J. Hruza, MD MBA, Kimberly Blumenthal, MD MSc, Lindy P. Fox, MD, Esther E. Freeman, MD PhD PII: S0190-9622(21)00658-7 DOI: https://doi.org/10.1016/j.jaad.2021.03.092 Reference: YMJD 15862 To appear in: Journal of the American Academy of Dermatology Received Date: 23 February 2021 Revised Date: 16 March 2021 Accepted Date: 26 March 2021 Please cite this article as: McMahon DE, Amerson E, Rosenbach M, Lipoff JB, Moustafa D, Tyagi A, Desai SR, French LE, Lim HW, Thiers BH, Hruza GJ, Blumenthal K, Fox LP, Freeman EE, Cutaneous Reactions Reported after Moderna and Pfizer COVID-19 Vaccination: A Registry-Based Study of 414 Cases, Journal of the American Academy of Dermatology (2021), doi: https://doi.org/10.1016/ j.jaad.2021.03.092. This is a PDF file of an article that has undergone enhancements after acceptance, such as the addition of a cover page and metadata, and formatting for readability, but it is not yet the definitive version of record. This version will undergo additional copyediting, typesetting and review before it is published in its final form, but we are providing this version to give early visibility of the article. Please note that, during the production process, errors may be discovered which could affect the content, and all legal disclaimers that apply to the journal pertain.
    [Show full text]
  • WFR Outline.Cwk
    WILDERNESS FIRST RESPONDER Nine Days (80 hours) Our Wilderness First Responder course is designed with the outdoor professional in mind. It focuses on developing skills for treating problems outside the “ golden hour” of first response. It is based on the protocols set by the Wilderness Medical Society and instruction encourages the students ability to think through body systems in an effort to determine the best response to traumatic, environmental or medical situations. Classroom sessions are followed with hands on practice to integrate the information in a field setting. 100% attendance is required and there will be a night scenario included. The students will get to see their skills in action as video coverage of intensive scenarios will be reviewed towards the end of the class. A comprehensive written exam is also administered. The course includes American CPR certification. General Syllabus Day 1: Basic Life Support Skills/ Anatomy and Physiology *Opening and Course Paperwork *Course Introduction and Expectations *Student and Instructor Introductions *Medical Legal Overview * Evolution of Patient Care System and how WFR’s fit in *Patient Assessment System (PAS) Part 1 How to approach a scene! General Review of Anatomy and Physiology (All Systems) *Specific exploration of Respiratory System *Hands on practice establishing an airway/airway management *Specific exploration of the Circulatory System * Hands on practice for checking for pulse, controlling bleeding, cpr *Specific exploration of Nervous System * Evaluating Level of Consciousness
    [Show full text]
  • Allergy, Hypersensitivity, Angioedema, and Anaphylaxis Episode Overview
    CrackCast Show Notes –Allergy and Anaphylaxis – October 2017 www.canadiem.org/crackcast Chapter 109 – Allergy, Hypersensitivity, Angioedema, and Anaphylaxis Episode Overview Key Points: 1. A history of sudden urticarial rash accompanied by respiratory difficulty, abdominal pain, or hypotension, strongly favors the diagnosis of anaphylaxis. 2. Epinephrine is the first-line treatment in patients with anaphylaxis: give it immediately. 3. There are no absolute contraindications to the use of epinephrine in the setting of anaphylaxis. 4. Antihistamines and corticosteroids are second- and third-line agents in the management of anaphylaxis and should not replace or precede epinephrine. 5. Consider prolonged observation or admission for patients who: a. Experience protracted anaphylaxis, hypotension, or airway involvement; b. Receive IV epinephrine or more than two doses of IM epinephrine; c. Or have poor outpatient social support. 6. Patients discharged after an anaphylactic event should be prescribed an EpiPen and instructed on its use. 7. Patients with refractory hypotension may require glucagon (receiving beta-blockage) or a continuous IV epinephrine infusion. 8. Non-histaminergic angioedema (non-allergic angioedema) does not typically respond to epinephrine and antihistamines. New drugs, including berinert, icatibant, ecallantide, and Ruconest have been approved for use in HAE. FFP has been used with varying success in HAE, ACID, and ACE inhibitor–induced angioedema. NOTE: ACID: acquired C1 esterase deficiency (ACED) Core Questions: 1. List the four types of Gell and Coombs classifications of immune reaction and give examples of each 2. List four etiologic agents causing anaphylaxis by immunologic mechanisms 3. List six mediators of anaphylaxis and their physiologic actions and clinical manifestations 4.
    [Show full text]